Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

if government regulation is stricter for the Group's new products than for existing treatments; - if the new products suffer a loss of patent protection or competitors successfully challenge or circumvent the Group's patents or regulatory exclusivity; - if planned geographical expansion into emerging markets is not successful; or - if the size of the patient population for the new product is less than expected or the Group fails to identify new patients for the new products.

If the Group is unable to commercialize ELAPRASE, VYVANSE, LIALDA, FIRAZYR, FOSRENOL (ROW) or any of its new products successfully, there may be a material adverse effect on the Group's revenues, financial condition and results of operations.

Any decrease in the combined sales of VYVANSE and ADDERALL XR will significantly reduce revenues and earnings

In 2008, the combined sales of VYVANSE and ADDERALL XR were $1,420.6 million, representing approximately 47% of the Group's total revenues. Sales of ADDERALL XR are expected to decrease significantly due to generic competition that is anticipated to commence on April 1, 2009. Any factors that decrease the sales of ADDERALL XR more significantly than expected could have a material adverse effect on the Group's financial condition and results of operations. In addition, the entrance of generic competitors for ADDERALL XR or other leading attention deficit and hyperactivity disorder ('ADHD') medications could impact the sales of VYVANSE. Other factors that could impact the sales of VYVANSE or ADDERALL XR include, but are not limited to:

    - faster than anticipated erosion of ADDERALL XR sales by
      generic competitors;

    - the development and marketing of competitive pharmaceuticals to VYVANSE
      and ADDERALL XR;

    - issues impacting the production of VYVANSE or ADDERALL XR or the supply
      of 
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 GEA Pharma Systems, G-CON ... recipients of the INTERPHEX Exhibitor Awards for 2015 ... Portable, Continuous, Miniature and Modular (PCMM) platform. PCMM ... continuous processing equipment, smart control systems and PODs ... and inactive ingredients into bulk tablets. , ...
(Date:5/4/2015)... , May 4, 2015 Many ... granted. But for certain infants with rare, inherited ... are stark consequences of their impaired immune responses. ... Center have identified an important role for calcium ... from Mycobacterium tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... its partners are pleased to announce the formation ... focussed on developing treatments for cancer that harness ... company represents a unique collaboration between the Children,s ... (CHEO) Research Institute, McMaster University, the Ontario Institute ...
Breaking Biology Technology:GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... Air Products (NYSE: APD ) and Alter ... a Joint Development Agreement (JDA) to pursue renewable energy ... agreement gives Air Products the right to license and ... use in renewable energy projects. Air Products will ...
... To say that LifeModeler, Inc. (LMI) bucked the ... 2008 that are providing a platform for even greater ... story. This past year will actually be considered ... literally expanded its presence in every category--from revenue and ...
... Inc.,(OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded,biopharmaceutical company ... Virus) and other infectious agents, today,announced that its Corporate ... be webcast live by Thomson Reuters. The Conference will ... on February 9 and 10, 2009. , ...
Cached Biology Technology:Air Products and Alter NRG Sign JDA on Renewable Energy Projects 2Air Products and Alter NRG Sign JDA on Renewable Energy Projects 3Air Products and Alter NRG Sign JDA on Renewable Energy Projects 4While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas 2While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas 3While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas 4GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 2GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 3
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... When your body cranks up the heat, its a ... help fight off the infection. But turning up the ... in 25 infants or small children, high fever can ... generally harmless, a prolonged fever resulting from infection or ...
... to chase down speeding vehicles as the movie Jurassic Park ... was certainly no slouch, research out today suggests. The ... the running speeds of five meat-eating dinosaurs that varied in ... The study believed to be the most accurate ever ...
... since the Manhattan project in World War II, ... technology. Yet,scientists still seek the ability to interpret ... and materials using first principle theory. Computational actinide ... PNNL scientist Jun Li will provide an overview ...
Cached Biology News:Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures 2T. rex quicker than Becks, say scientists 2
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Qa-1 (L-12)...
... Coated Capture Antibody: 12 x 8-well strips, 3 ... of 2X concentrate , Beta Amyloid 1-40 ... Lyophilized Standard Diluent: 3 mL , Primary Antibody: ... 30 microL of concentrate , OPD Substrate: 20 ...
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Biology Products: